Depression and Leukocyte Telomere Length in Patients With Coronary Heart Disease: Data From The Heart and Soul Study

PETRA W. HOEN, BSC, PETER DE JONGE, PHD, BEE YA NA, MPH, RAMIN FARZANEH-FAR, MD, ELISSA EPEL, PHD, JUE LIN, PHD, ELIZABETH BLACKBURN, PHD, AND MARY A. WHOOLEY, MD

Objective: Shortened telomere length has been associated with mortality in patients with coronary heart disease (CHD) and is considered as an emerging marker of biologic age. Whether depression is associated with telomere length or trajectory has not been evaluated in patients with CHD. Methods: In a prospective cohort study, we measured leukocyte telomere length in 952 participants with stable CHD at baseline and in 608 of these participants after 5 years of follow-up. The presence of major depressive disorder in the past month was assessed using the computerized diagnostic interview schedule at baseline. We used linear and logistic regression models to evaluate the association of depression with baseline and 5-year change in leukocyte telomere length. Results: Of the 952 participants, 206 (22%) had major depression at baseline. After the adjustment for age and sex, the patients with current major depressive disorder had shorter baseline telomere length than those without depression (mean [standard error] = 0.86 [0.02] versus 0.90 [0.01]; p = .02). This association was similar (but no longer statistically significant) after adjustment for body mass index, smoking, diabetes, left ventricular ejection fraction, statin use, antidepressant use, physical inactivity, and anxiety (0.85 [0.02] versus 0.89 [0.01], p = .06). Depression was not predictive of 5-year change in telomere length after adjustment for the mentioned covariates and baseline telomere length. Conclusions: Depression is associated with reduced leukocyte telomere length in patients with CHD but does not predict 5-year change in telomere length. Future research is necessary to elucidate the potential mechanisms underlying the association between depression and telomere length. Key words: depression, telomere length, stable CHD.

CHD = coronary heart disease; MDD = major depressive disorder; CDIS-IV = computerized diagnostic interview schedule; MI = myocardial infarction; PHQ = Patient Health Questionnaire; BMI = body mass index; LVEF = left ventricular ejection fraction.

INTRODUCTION

Telomeres are specialized tandem deoxyribonucleic acid (DNA) repeat sequences (TTAGGG)n located at the ends of eukaryotic chromosomes, which protect somatic cells from genomic instability during mitotic cell proliferation (1). During mitosis, the telomere is not fully replicated because of the inherent properties of DNA polymerase, resulting in obligate telomere shortening with each cell division. Eventually, telomere shortening can result in cessation of mitosis (senescence) or programmed cell death (apoptosis) (2). Thus, telomere attrition has been proposed as the basis for a ‘biologic clock’ that integrates the cumulative effect of environmental stressors independently of chronological age (3).

Since the discovery of telomeres, there is a growing body of literature linking shortened telomeres with increased age-related morbidity and mortality. Previous studies have found that psychological distress is associated with short telomere length in otherwise healthy adults (4–6) and in older patients with heart failure (7). However, the association between depression and telomere length has not been evaluated in patients with coronary heart disease (CHD). Furthermore, the effect of depression on subsequent change in telomere length over time has not been examined in any patient population. Evaluating this effect is of importance for our understanding of human telomere biology over time in depressed patients.

Both depression and short telomere length predict mortality in patients with CHD (8–11). Whether depression is associated with leukocyte telomere length or telomere trajectory among patients with stable CHD is unknown. We sought to investigate the association among depression, telomere length, and telomere trajectory in a prospective cohort study of patients with stable CHD. In addition, we evaluated whether differences in leukocyte telomere length might contribute to the adverse cardiovascular outcomes associated with depressive symptoms.

METHODS

Design and Participants

The Heart and Soul Study is a prospective cohort study focused on psychosocial factors and health outcomes in patients with stable CHD. Details regarding the study design have been described previously (12). Between September 2000 and December 2002, 1024 patients were recruited from 12 outpatient clinics in San Francisco Bay Area. Inclusion criteria were history of myocardial infarction (MI) or coronary revascularization, angiographic evidence of at least 50% stenosis in at least one coronary vessel, or a diagnosis of CHD by an internist or cardiologist. Patients were excluded if they had a history of MI in the past 6 months, were unable to walk one block, or were planning to move out of the local area within 3 years. Patients underwent a baseline study...
examination that included a comprehensive health interview, blood samples, medical history, questionnaire, psychosocial questionnaire, and exercise treadmill test with stress echocardiography. Of the 1024 enrolled patients, 954 provided DNA samples for the analysis at baseline, and 608 of these participants provided DNA samples again after 5 years of follow-up (13). The study protocol was approved by the appropriate institutional review boards, and all participants signed an informed consent.

Assessment of Depression

We ascertained the presence of major depressive disorder (MDD) in the past month according to Diagnostic and Statistical Manual, Fourth Edition, criteria. We used the modified Computerized National Institute of Mental Health Diagnostic Interview Schedule (CDIS-IV), a highly structured interview designed to yield psychiatric diagnosis (14). The CDIS-IV is a validated computerized version of the health care professional–administered, structured clinical interview for the diagnosis of psychiatric illness. Trained research assistants administered the interview during the daylong study appointment. We also assessed the presence and severity of depressive symptoms using the nine-item Patient Health Questionnaire (PHQ-9) (15). The PHQ-9 is a self-report checklist derived from the Primary Care Evaluation of Mental Disorders interview (16). The PHQ-9 measures the presence of depressive symptoms during the previous 2 weeks (0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly everyday). We evaluated PHQ as a continuous variable (range = 0–27).

Telomere Length Assay

Details regarding telomere length assay in The Heart and Soul Study have been described previously (13). Telomere length measurements were performed in a blinded fashion without the knowledge of depression status. According to standard procedures, genomic DNA was isolated from the peripheral blood leukocytes that were stored at −70°C. Purified DNA samples were diluted in 96-well microtiter source plates to a fixed concentration of 3 ng/µL. A quantitative polymerase chain reaction–based assay was used to measure the relative mean telomere length. This assay compares the mean telomere repeat sequence copy number (T) to a reference single copy gene copy number (S) in each sample. Standard curves were derived from serially diluted reference DNA. The T/S ratio was calculated from the average quantity of the reference DNA found with each experimental sample for the copy number of the targeted template (for T: the number of telomere repeats, and for S: the number of β-globin gene copies). The equation for conversion from T/S ratio to base pairs for this study was base pairs = 3274 + 2413 × (T/S) (13). The inter-assay coefficient of variability for telomere length measurement was 3.7%, and the intra-assay coefficient of variability was 2.5%.

Other Baseline Characteristics

Age, sex, ethnicity, education, smoking status, and alcohol use were determined by the questionnaire. Weight and height were measured, and body mass index (BMI, kg/m²) was calculated. Comorbid conditions were determined by self-report and included hypertension, MI, congestive heart failure, and diabetes mellitus. Anxiety was assessed with the Hospital Anxiety and Depression Scale. We assessed left ventricular ejection fraction (LVEF) using a resting echocardiography. Resting systolic and diastolic blood pressure was measured manually using a standard sphygmomanometer. To assess physical activity, we asked, “Which of the following statements best describes how physically active you have been during the last month, that is, done activities such as 15 to 20 minutes of brisk walking, swimming, general conditioning, or recreational sports?” The participants chose from one of the following six categories: not at all active, a little active (1–2 times per month), fairly active (3–4 times per month), quite active (1–2 times per week), very active (3–4 times per week), or extremely active (≥5 times per week). Self-report has been shown to be a reliable, valid, and accurate method of assessing physical activity (17,18). The participants who reported that they were not at all or a little active were considered physically inactive. Low- and high-density lipoprotein cholesterol levels were determined from fasting venous blood samples. The participants were instructed to bring their medication bottles to their appointment, and study personnel recorded all current medications, including dose and frequency use.

Heart Failure and Death

To determine whether differences in leukocyte telomere length might contribute to the adverse cardiovascular outcomes associated with depressive symptoms, we evaluated the association of depressive symptoms with mortality before and after the adjustment for baseline telomere length. Annual telephone interviews were conducted with participants or their proxies asking about emergency department visits, hospitalizations, or death. For any reported event, medical records, death certificates, and coroner’s reports were reviewed by two independent blinded adjudicators. In the event of disagreement, a third blinded adjudicator reviewed the event and determined the outcome variable. To be diagnosed with heart failure, patients had to be hospitalized for a clinical syndrome involving an acute change in at least two of the following: paroxysmal nocturnal dyspnea, orthopnea, elevated jugular venous pressure, pulmonary rales, third heart sound, cardiomegaly, or pulmonary edema on chest radiography. Death was confirmed by review of death certificates.

Statistical Analyses

For descriptive purposes, the participants were grouped based on the presence or absence of current major depression (by CDIS-IV) and compared on clinical and demographic variables, using t tests and χ² tests. Telomere length was normally distributed. For primary analyses, the association between depression and mean telomere length at baseline was examined using generalized linear models (for telomere length as a continuous variable) and logistic regression for short telomere length, defined a priori as having leukocyte telomere length in Quartile 1 versus 4.

Percent change in telomere length was calculated as [(follow-up T/S − baseline T/S) × 100] divided by baseline T/S. The association between depression and the 5-year change in telomere length was assessed using generalized linear models (for percent change in telomere length as a continuous variable) and logistic regression models for predicting telomere shortening (defined as a priori as a >10% decrease in telomere length) versus maintained (±10% change in telomere length) or lengthened (>10% increase in telomere length) (13). For multivariable models, the following covariates were chosen based on cross-sectional associations with telomere length and depression: age, sex, diabetes, BMI, smoking, LVEF, statin use, antidepressant use, physical inactivity, and anxiety (9). To determine whether the effect of depression on telomere trajectory differed in patients with shorter or longer baseline telomere length, we tested an interaction term (depression by baseline telomere length) as a predictor of shortening.

We have previously reported that depressive symptoms, but not MDD, predict subsequent heart failure and death in The Heart and Soul Study (19). To evaluate whether telomere length may be a mediator in this association, we estimated the association of depressive symptoms with heart failure or death using Cox proportional hazard models, with and without the adjustment for baseline telomere length. Statistical analyses were performed using SAS software version 9.1 (SAS Institute Inc, Cary, North Carolina).

RESULTS

Of the 954 patients who provided DNA samples for the analysis at baseline, two had no CDIS measurement, leaving 952 patients to be included in further analyses. The baseline characteristics of the study population categorized by current depression are presented in Table 1. Of the 952 patients, 206 (22%) participants had current (past month) depression. Compared with participants who did not have depression, those with depression were younger and less likely to be male. They were more likely to have higher LVEF, to smoke, to have diabetes mellitus, to have a higher anxiety score, to use antidepressants, and to be physically inactive, but less likely to use statins.

Depression and Baseline Telomere Length

After adjustment for age and sex, patients with current MDD had shorter telomere length than patients without current
depression (mean [standard error] = 0.86 [0.02] versus 0.90 [0.01], \( p = .02 \)). This association was similar (but no longer statistically significant) after further adjustment for BMI, smoking, diabetes, LVEF, statin use, antidepressant use, physical inactivity, and anxiety (0.85 [0.02] versus 0.89 [0.01], \( p = .06 \); Table 2). The difference of 0.04 T/S units is comparable with 97 base pairs. Compared with nondepressed participants, those with major depression had a 71% greater odds of having short telomere length (adjusted odds ratio = 1.71, 95% confidence interval [CI] = 0.98–2.98, \( p = .06 \); Table 3). When entered as a continuous variable, higher depressive symptom scores were also associated with shorter telomere length, adjusted for age, sex, diabetes, BMI, smoking, LVEF, and statin use (β coefficient = −0.00297, \( p = .03 \)). Again, this association was

---

**TABLE 2. Telomere Length (Analyzed as a Continuous Variable, Mean [Standard Error]) by the Presence of Major Depressive Disorder Among 952 Participants at Baseline**

<table>
<thead>
<tr>
<th>Adjusted for</th>
<th>Current Depression (( n = 206 ))</th>
<th>No Current Depression (( n = 746 ))</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age and sex</td>
<td>0.86 (0.02)</td>
<td>0.90 (0.01)</td>
<td>.02</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, and smoking</td>
<td>0.86 (0.02)</td>
<td>0.89 (0.01)</td>
<td>.04</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity, and antidepressant use</td>
<td>0.85 (0.02)</td>
<td>0.89 (0.01)</td>
<td>.04</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity, and antidepressant use, and anxiety</td>
<td>0.85 (0.02)</td>
<td>0.89 (0.01)</td>
<td>.06</td>
</tr>
</tbody>
</table>

BMI = body mass index; LVEF = left ventricular ejection fraction.
TABLE 3. Association Between Major Depressive Disorder and Short Telomere Length (Analyzed as a Dichotomous Variable, Quartile 1 Versus 4)

<table>
<thead>
<tr>
<th>Adjusted for</th>
<th>Odds Ratio (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age and sex</td>
<td>1.73 (1.08–2.79)</td>
<td>.02</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, and smoking</td>
<td>1.65 (1.03–2.67)</td>
<td>.04</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity, and antidepressant use</td>
<td>1.72 (1.02–2.89)</td>
<td>.04</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity, antidepressant use, and anxiety</td>
<td>1.71 (0.98–2.98)</td>
<td>.06</td>
</tr>
</tbody>
</table>

CI = confidence interval; BMI = body mass index; LVEF = left ventricular ejection fraction.

no longer statistically significant after further adjustment for antidepressant use, physical inactivity, and anxiety ($\beta$ coefficient = $-0.00231$, $p = .17$).

Depression and 5-Year Change in Telomere Length

Of the 1024 original enrollees, 195 had died before the 5-year examination, and 667 (80%) of the eligible 829 participants completed the 5-year follow-up examination. Of the 667 participants who completed the 5-year examination, 59 were missing telomere length measurements at baseline and/or follow-up, leaving 608 participants for the analysis of the 5-year change. Compared with the 221 participants who were alive at 5 years but not included in the analyses, these 608 participants had similar age and baseline telomere length. Overall, 276 participants (45%) experienced telomere shortening, 192 (32%) maintained their telomere length (±10%), and 140 experienced telomere lengthening (23%). Compared with the 481 nondepressed participants, the 127 participants with MDD at baseline were less likely to experience telomere shortening (35% versus 48%) and more likely to experience telomere lengthening (26% versus 21%; Fig. 1). After adjustment for age, sex, diabetes, BMI, smoking, LVEF, statin use, antidepressant use, physical inactivity, and anxiety, MDD was associated with a 32% decreased odds of shortening. However, this association was not significant after further adjustment for shorter baseline telomere length in the depressed participants (odds ratio = 0.76, 95% CI = 0.40–1.44, $p = .40$; Table 4).

When the 5-year percent change in telomere length was analyzed as a continuous variable, participants with MDD were also less likely to experience telomere shortening than those without depression (percent change = $-0.9%$ [2.4%] versus $-6.6%$ [1.9%]; $p = .03$), adjusted for age, sex, diabetes, BMI, smoking, LVEF, statin use, antidepressant use, physical inactivity, and anxiety. Again, this association was no longer significant after adjustment for shorter baseline telomere length in the depressed participants (percent change = $-3.0%$ [1.7%] versus $-5.6%$ [1.3%]; $p = .13$; Table 5). We found no evidence that the effect of depression on change in telomere length differed in patients with shorter or longer baseline telomere length ($p$ for interaction = .78).

Depressive Symptoms and Cardiovascular Outcomes

As of December 18, 2009, vital status was known for 949 (>99%) of the 954 study participants, and there were 277 deaths. Each standard deviation (5.5-point) increase in PHQ depressive symptom score was associated with a 16% increased rate of death (age-adjusted hazard ratio [HR] = 1.16, 95% CI = 1.04–1.31, $p = .01$) and a 24% increased rate of heart failure (HR = 1.24, 95% CI = 1.07–1.45, $p = .006$). The adjustment for shorter baseline telomere length in the depressed patients did not affect these associations (HR = 1.14, 95% CI = 1.01–1.28, $p = .03$ for death; HR = 1.23, 95% CI = 1.05–1.44, $p = .009$ for heart failure).

DISCUSSION

In a sample of 952 patients with stable CHD, we found that major depression was associated with a 71% greater odds of having short telomere length. The participants with major depression had an average telomere length that was 97 base pairs shorter than those without depression. Assuming an average

TABLE 4. Association Between Major Depressive Disorder and Subsequent Shortening in Leukocyte Telomere Length (>10% Decrease)

<table>
<thead>
<tr>
<th>Adjusted for</th>
<th>Odds Ratio (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, sex</td>
<td>0.66 (0.43–1.00)</td>
<td>.05</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, smoking</td>
<td>0.67 (0.44–1.01)</td>
<td>.06</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity, and antidepressant use</td>
<td>0.63 (0.40–0.99)</td>
<td>.04</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity, antidepressant use, and anxiety</td>
<td>0.68 (0.42–1.12)</td>
<td>.13</td>
</tr>
<tr>
<td>Age, sex, diabetes, BMI, smoking, LVEF, statin use, physical inactivity, antidepressant use, anxiety, and baseline telomere length</td>
<td>0.76 (0.40–1.44)</td>
<td>.40</td>
</tr>
</tbody>
</table>

CI = confidence interval; BMI = body mass index; LVEF = left ventricular ejection fraction.

Figure 1. Proportion of participants who experienced telomere shortening, maintenance, or lengthening, during the 5 years of follow-up ($p = .03$ from overall $\chi^2$), unadjusted for age or baseline telomere length.
Oxidative stress has a negative effect on telomere length, through proinflammatory cytokines have been found to influence telomere length. Previous studies have demonstrated an association between depression and oxidative stress. Depressed patients have increased levels of circulating oxidative stress markers and decreased levels of antioxidant enzymes (20). Previous cross-sectional studies have found that psychosocial factors are associated with shorter telomere length, but the relation between depression and telomere length has not previously been evaluated in patients with CHD. Epel et al. (4) demonstrated that the chronicity and perceived severity of psychosocial stress was directly associated with accelerated telomere shortening in middle-aged healthy women (n = 65). Simon et al. (6) measured leukocyte telomere length in 44 individuals with chronic mood disorders and 44 nonpsychiatric ill age-matched control subjects and found that telomere length was significantly shorter in those with mood disorders. Lung et al. (5) found an association between depression and short telomere length among 253 depressed patients compared with 411 community controls. Another study found that poor perceived mental health, but not depressive symptoms, was associated with shorter telomere length in 890 patients with congestive heart failure (7). Our study adds to this growing literature by demonstrating that depression is associated with shorter telomere length in patients with CHD. In addition, our findings demonstrate that, although associated with shorter baseline telomere length, current depression does not predict subsequent shortening.

Underlying Mechanisms

Further research is necessary to examine the mechanisms underlying the association between depression and reduced telomere length in CHD patients. Potential links between depression and shortened telomere length could be oxidative stress and inflammation (20). Previous studies have demonstrated an association between depression and oxidative stress. Depressed patients have increased levels of circulating oxidative stress markers and decreased levels of antioxidant enzymes (21–23). In addition, some, but not all studies, have found that depression is associated with increased levels of proinflammatory cytokines (24,25). Both oxidative stress and proinflammatory cytokines have been found to influence telomere length. Oxidative stress has a negative effect on telomere length, through inhibition of telomerase activity (26) and direct erosion of GGG triplets in telomeric DNA (27). Proinflammatory cytokines may either decrease or increase telomerase activity (28–30) and are thought to lead to immune cell turnover, and thus decreased telomere length through greater replicative history.

Depression and Baseline Telomere Length

Little is known concerning the dynamic regulation of telomere length over time. Recently, it has become apparent that telomeres may lengthen and shorten (13,31). In our sample, less than half of the participants experienced telomere shortening, and almost a quarter actually lengthened their telomeres during the 5-year follow-up period. In this longitudinal study we observed that MDD was associated with a 32% decreased odds of shortening (i.e., greater odds of lengthening). However, short baseline telomere length is by far the strongest predictor of subsequent lengthening, and this association was not significant after further adjustment for shorter baseline telomere length in depressed participants. Therefore, depression does not seem to predict 5-year subsequent change in telomere length independently. These findings are in concordance with the previous studies that found that telomere trajectory is powerfully influenced by baseline telomere length and that both healthy individuals and CHD patients with the longest telomeres experienced the greatest amount of shortening, whereas those with shorter telomeres either maintained or increased in their length (13,31,32).

An important regulator of this negative feedback is the enzyme telomerase, which is a reverse transcriptase enzyme that restores telomere length. Telomerase has been shown to act preferentially on short telomeres in mice models and cell culture systems (33–36). Moreover, chronically stressed caregivers who are also high in depressive symptoms have increased levels of telomerase (37). Thus, it is possible that depression may have contributed to shorter baseline telomeres, but over a follow-up time of 5 years, the subsequent negative feedback from those short telomeres may overwhelm any independent effect on trajectory. Alternatively, the current findings are consistent with a model in which depression is a consequence of short telomeres or in which a shared (genetic) risk factor is responsible for both depression and short telomere length at baseline.
Depression and Mortality

Currently, a large body of literature has confirmed that depressive symptoms are associated with greater mortality among patients with established CHD (8,11). A recent study showed that shorter telomere length was associated with all-cause mortality and heart failure in patients with stable CHD (9). Because depression is associated with shorter telomere length, this raises the question of whether accelerated cellular aging is a mechanism that contributes to the excess morbidity and mortality associated with depression (6,38). To our knowledge, we are the first study that evaluates whether shortened telomere length may potentially underlie the relationship between depression and heart failure and mortality. The adjustment for baseline telomere length in the depressed patients did not affect the association between depression and prognosis.

Strengths and Limitations

Our study has several strengths, including repeated measurements of telomere length; measurement of multiple potential confounding variables including BMI, LVEF, smoking, and physical inactivity; and detailed assessments of depression. However, some limitations of this study should be noted. First, this study included stable CHD patients and mainly older men. Thus, the results may not generalize to women or to healthy or acute coronary syndrome populations. Second, we did not measure the impact of telomerase activity on the prognostic value of leukocyte telomere length. Third, telomere length measurements were restricted to circulating leukocytes, do not necessarily reflect telomere length in other cell compartments, and do not inform about accelerated aging of any particular immune cell subpopulation. Fourth, the association between depression and shortened telomere length may have been the result of greater cardiac disease severity in depressed patients, although we attempted to address this possibility by carefully measuring and adjusting for cardiovascular disease severity. Fifth, the severity of depressive symptoms was relatively low with an average PHQ score of 10.7 among depressed participants. Finally, we did not assess the chronicity or duration of depression at the baseline examination nor did we account for continued depression or other psychiatric diagnoses at follow-up.

CONCLUSIONS

To our knowledge, this is the first study to examine and report an association between depression and telomere length in patients with stable CHD. In summary, we found that patients with current depression had a shorter telomere length at baseline. However, current depression did not predict subsequent change in telomere length. Future research is necessary to elucidate the mechanism underlying the association between depression and telomere length.

REFERENCES


